These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23622697)

  • 1. Characterization of mitotane (o,p'-DDD)--cyclodextrin inclusion complexes: phase-solubility method and NMR.
    Alfonsi R; Attivi D; Astier A; Socha M; Morice S; Gibaud S
    Ann Pharm Fr; 2013 May; 71(3):186-92. PubMed ID: 23622697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melarsoprol-cyclodextrins inclusion complexes.
    Gibaud S; Zirar SB; Mutzenhardt P; Fries I; Astier A
    Int J Pharm; 2005 Dec; 306(1-2):107-21. PubMed ID: 16253447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of inclusion complexes formed between baicalein and cyclodextrins.
    Zhou Q; Wei X; Dou W; Chou G; Wang Z
    Carbohydr Polym; 2013 Jun; 95(2):733-9. PubMed ID: 23648035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells.
    Asp V; Cantillana T; Bergman A; Brandt I
    Xenobiotica; 2010 Mar; 40(3):177-83. PubMed ID: 20044879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
    Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins.
    Jullian C; Morales-Montecinos J; Zapata-Torres G; Aguilera B; Rodriguez J; Arán V; Olea-Azar C
    Bioorg Med Chem; 2008 May; 16(9):5078-84. PubMed ID: 18375132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies.
    Phillip Lee YH; Sathigari S; Jean Lin YJ; Ravis WR; Chadha G; Parsons DL; Rangari VK; Wright N; Babu RJ
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1113-20. PubMed ID: 19640249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.
    Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cyclodextrin solubilization of drugs.
    Loftsson T; Hreinsdóttir D; Másson M
    Int J Pharm; 2005 Sep; 302(1-2):18-28. PubMed ID: 16099118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
    Lindhe O; Skogseid B
    Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclodextrin complexation on aqueous solubility and photostability of phenothiazine.
    Lutka A
    Pharmazie; 2000 Feb; 55(2):120-3. PubMed ID: 10723770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexation of morin with three kinds of cyclodextrin. A thermodynamic and reactivity study.
    Jullian C; Orosteguis T; Pérez-Cruz F; Sánchez P; Mendizabal F; Olea-Azar C
    Spectrochim Acta A Mol Biomol Spectrosc; 2008 Nov; 71(1):269-75. PubMed ID: 18262835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of microemulsion of mitotane for improvement of oral bioavailability.
    Attivi D; Ajana I; Astier A; Demoré B; Gibaud S
    Drug Dev Ind Pharm; 2010 Apr; 36(4):421-7. PubMed ID: 19778161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient.
    Dickerman Z; Kaufman H; Laron Z
    Isr J Med Sci; 1979 May; 15(5):455-9. PubMed ID: 447515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) in rats.
    Reif VD; Sinsheimer JE
    Drug Metab Dispos; 1975; 3(1):15-25. PubMed ID: 234830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients.
    Garg MB; Sakoff JA; Ackland SP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2201-5. PubMed ID: 21719363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.